Our findings further demonstrate that similar GNAS molecular alterations may lead to a broad spectrum of diseases, from isolated PTH resistance to multi-hormone resistance and Albright hereditary osteodystrophy Objectives: To collect patients with the following characteristics: clinical PHP-I (with or without AHO), no mutation in Gs-coding sequence but presence of GNAS methylation alterations; to investigate the existance of correlations between the degree of the epigenetic defect and the severity of the disease.
Introduction
Pseudohypoparathyroidism (PHP) and Albright hereditary osteodystrophy (AHO) (short stature, rounded face, brachydactyly, ectopic ossifications and mental retardation) are rare, related, highly heterogeneous and deeply impairing disorders with proven genetic component. PHP is historically the first hormone resistance syndrome, and the term now encompasses a heterogeneous group of metabolic diseases, all characterized by end-organ resistance to the action of PTH On the other hand, the majority of PHP-Ib patients, who classically display hormone resistance limited to PTH and TSH with no AHO sign and normal Gsα activity in erythrocytes and fibroblast, display methylation defects in the imprinted GNAS cluster (5, 6) . In fact, beside Gsα, GNAS drives the transcription of other genes, including XLαs, A/B, NESP55 and AS, each promoter being characterized by a parent-specific methylation pattern ( Figure 1 ) (reviewed in refs.
7&8). The most consistent defect common to all PHP-Ib patients is the loss of imprinting at the exon A/B differentially methylated region (DMR), and the percent of methylation at this site seems to correlate with PTH concentration at the time of diagnosis (6, 9) . The biallelic and thus abnormal expression of this paternally derived transcript located upstream of the gene encoding Gsα, presumably leads to a decreased Gsα expression in renal proximal tubules and few additional cells.
The familial form of the disease (AD-PHP-Ib) is typically caused either by an isolated loss of imprinting at the exon A/B DMR due to microdeletions disrupting the upstream STX16 gene or, less frequently, by loss of all the maternal GNAS imprints associated with deletions removing the NESP55 DMR. Conversely, sporadic PHP-Ib cases show broad GNAS imprinting abnormalities involving multiple DMRs, with no known underlying genetic lesion (reviewed in refs. 10&11).
During the last decade, incoming data on both clinical and molecular aspects of these complex disorders have challenged the distinction of different GNAS-related diseases. In particular, in a subset of patients with PHP and variable degrees of AHO, epigenetic defects of GNAS similar to those classically found in PHP−Ib patients have been detected by independent groups, suggesting a molecular overlap between PHP-Ia and Ib (12) (13) (14) (15) , but the correlation between these molecular findings and the severity of the disease has not been elucidated. In the present study we therefore investigated the presence of correlations between the degree of epigenetic defects and the severity of the disease in a large series of patients with PHP type I.
Patients and Methods

Patients
The inclusion criteria in the present study were the presence of PHP together with methylation defects at the GNAS locus in the absence of mutations in GNAS Gsα-coding exons.
Following these criteria, we included 54 patients (23 females and 31 males), all born from healthy, non-consanguineous parents. In all of them the clinical diagnosis of PHP was based upon the presence of PTH resistance, i.e. hypocalcemia, hyperphosphatemia and raised serum PTH levels in the absence of vitamin D deficiency. Twelve patients presented with additional hormone resistances and at least two of the six AHO manifestations: brachydactyly (shortening of fourth and/or fifth metacarpals defined as the metacarpal sign and/or shortening below -2SDS at the metacarpophalangeal profile pattern in at least one metacarpal bone or distal phalanx) (12,16), short stature (height below the 3th percentile for chronological age), obesity (BMI >30 kg/m 2 in adults and >97 th centile in children), round face, ectopic ossifications (either clinically evident or at X-ray), and mental retardation, defined in case of history of delayed motor and/or speech milestones or need of extra help in pre-school or mainstream school. Since many of these signs are highly non-specific, the presence of at least brachydactyly and/or heterotopic ossifications was required for the definition of AHO. In this case, despite the absence of mutations in GNAS Gsα-coding exons, a clinical diagnosis of PHP-Ia was made.
In the remaining 42 patients PTH resistance presented either alone or, as for more than half of these patients (N=17), together with TSH resistance. In addition to the absence of distinguishing AHO signs (brachydactyly and ectopic ossifications), no other hormone resistances were observed in this series. These patients were thus classified as having PHP-Ib.
The age at which diagnosis of PHP-I was made ranged between 3 and 51 year-old (mean age: 14 for PHP-Ia patients and 36 for PHP-Ib patients). Clinical and biochemical details are shown in Table 1 . Informed consent for genetic and epigenetic studies was obtained from all subjects involved in the study.
GNAS Methylation analysis and quantification
Differential methylation of GNAS DMRs A/B, AS, XL, and NESP was assessed on bisulfitetreated DNA using highly quantitative analysis based on PCR-pyrosequencing, as previously reported (15) . In brief, 360 ng DNA were treated using the EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA) according to the manufacturer's protocol, and were amplified by PCR using ZymoTaq DNA Polymerase (Zymo Research, Orange, CA). Primers for the amplification of the four different GNAS exons were specifically designed to amplify bisulfite-modified DNA (primer sequences available upon request). Either the forward or the reverse primer was biotin-labeled, depending on the proximity to CG sites, in order to be quantified and used to purify the final PCR product using Sepharose beads. The PCR product was bound to Streptavidin Sepharose HP (Amersham Biosciences, Uppsala, Sweden), and the Sepharose beads containing the immobilized PCR product were purified, washed, denatured using a 0.2M NaOH solution, and washed again using the Pyrosequencing Vacuum Prep Tool (Pyrosequencing, Westborough, MA), as recommended by the manufacturer. A 0.3 µM pyrosequencing primer was then annealed to the purified single-stranded PCR product, and pyrosequencing was performed using the PyroMark MD (Pyrosequencing) (Figure 2 ). Every sample was tested three times for each marker to confirm the reproducibility of our results. Methylation quantification was performed using the provided software. The degree of methylation was expressed for each considered DNA DMR as percentage Similarly, no correlation was observed in our study between the degree of methylation defects and the severity of AHO, defined as the number of AHO signs (r=-0.01041, P=0.9404, Spearman's correlation test) or the presence or absence of each sign in patients affected with clinically defined PHP-Ia (Table 1 and Ib (12) (13) (14) (15) . This would propose that features of AHO may result from either mutations in Gsα−coding exons or epigenetic defects causing disruption of imprinting control elements in GNAS locus, both defects resulting in silencing or reduction of Gsα transcription in selected tissues, where it is postulated that the protein is mainly derived from the maternal allele (17) (18) (19) (20) .
According to this line of evidence, the present study further expands the number of patients with PHP and AHO carrying GNAS methylation abnormalities, thus confirming all recently published reports by us and others.
To date, although we previously reported that the presence or absence of imprinting defects in clinically classified PHP-Ia patients was not associated with the severity or number of signs of AHO, as well as number or type of hormone resistances (15) , no study has investigated the existence of an epigenotype/phenotype correlation in PHP-I patients. In this study we therefore aimed to investigate the presence of a correlation between the degree of epigenetic defects and the severity of the disease in a very large series of these patients. The data presented here confirm the absence of correlation between the phenotype of 54 PHP-I patients and their epigenotype, Moreover, the authors also found a sub-cluster of patients who did not show any abnormality at the XL DMR, despite having alterations at all the other DMRs (A/B, NESP and AS). Noteworthy, in our series a small subset of patients (pts 5, 9, 38 and 43) may belong to this entity as they display higher levels of methylation at the XL DMR than those detected at the other investigated DMRs.
However, statistical analysis did not identify this cluster of patients and, anyhow, no phenotypic difference was observed in these cases if compared with the others. In our study, pyrosequencing . Nevertheless, the latter hypothesis is unlikely in this case series as most of our patients were previously found to be heterozygous for at least one polymorphic site within GNAS (15) .
In the present study, all patients displaying both hormone resistance and AHO were clinically classified as having PHP-Ia. Therefore, we did not make a distinction between PHP-Ia and PHP-Ic, as a large subset of these patients were not evaluated for Gsα activity. Measurement of Gsα activity in erythrocyte membranes is considered crucial to distinguish PHP-Ia subjects from PHP-Ic ones, being reduced in the former group and normal in the latter. Similarly to PHP-Ic, this activity is classically normal in PHP-Ib patients. Indeed, a very recent study demonstrated a reduction of Gsα activity in erythrocyte membranes of patients with PHP due to epigenetic alterations at the GNAS locus, the maximum decrease being observed in patients with AHO signs (30). The absence of GNAS mutations is the second hallmark of PHP-Ic. Nevertheless, mutations in GNAS carboxyl-terminus with conserved adenylyl cyclase receptor-independent activation but disrupted receptor-mediated activation have been recently detected in few PHP-Ic patients (31,32).
Taken together, these findings further underscore the overlap among PHP-I subtypes and suggest that PHP-Ia and -Ic are indeed clinically, biochemically and genetically indistinguishable disorders.
Finally, the severity of hormone resistance in PHP-Ia and Ib has not been deeply investigated to date, with the exception of a single paper reporting the absence of clinical differences between the sporadic and the familial form of PHP-Ib (33). Taken advantage of the large number of patients included in this study, we also compared patients clinically classified as having PHP-Ia in respect with those affected with PHP-Ib and no difference was found in terms of calcium and PTH levels at the time of diagnosis, as well as TSH and phosphorus levels.
In conclusion, we describe a large, clinically and molecularly characterized series of patients affected with PHP type I, in whom we performed a phenotype/epigenotype correlation analysis. Our findings demonstrate that similar GNAS molecular alterations may equally lead to a broad spectrum of diseases, from isolated PTH resistance to multi-hormone resistance associated with Albright hereditary osteodystrophy. Despite we strongly believe that each PHP patient should be screened for both GNAS genetic and epigenetic alterations in order to have a proper genetic counselling, the data presented here do not suggest that the molecular characterization may help clinicians to anticipate the severity and the type of different PHP/AHO manifestations. The table summarizes data analysis by Coffalyser software in a wild-type sample and in samples
